Regulation of platelet plug formation by phosphoinositide metabolism

Blood

Volumn 122, Issue 8, 2013, Pages 1358-1365

  Min, Sang H ^a   Abrams, Charles S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; LIPID KINASE; LIPID PHOSPHATASE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; ISOPROTEIN; POLYPHOSPHOINOSITIDE;

CELL ADHESION; CELL MEMBRANE; CELLULAR DISTRIBUTION; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INTRACELLULAR SIGNALING; INTRACELLULAR SPACE; MAMMAL CELL; MEGAKARYOCYTE; MOUSE; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PLECKSTRIN HOMOLOGY DOMAIN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SECOND MESSENGER; SEQUENCE HOMOLOGY; SYNTHESIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; ALTERNATIVE RNA SPLICING; ANIMAL; CYTOLOGY; HUMAN; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

ALTERNATIVE SPLICING; ANIMALS; BLOOD PLATELETS; HUMANS; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHATIDYLINOSITOLS; PLATELET ACTIVATION; PLATELET AGGREGATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84886851036     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-427716     Document Type: Review

References (87)

1. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17(11): 1423-1436.
2. Stalker TJ, Newman DK, Ma P, Wannemacher KM, Brass LF. Platelet signaling. Handb Exp Pharmacol. 2012;210:59-85.
3. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109(12):5087-5095.
4. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007; 100(12):1673-1685.
5. Hokin MR, Hokin LE. Enzyme secretion and the incorporation of P32 into phospholipides of pancreas slices. J Biol Chem. 1953;203(2): 967-977.
6. Hokin LE. History of phosphoinositide research. Subcell Biochem. 1996;26:1-41.
7. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443(7112):651-657.
8. Krauss M, Haucke V. Phosphoinositidemetabolizing enzymes at the interface between membrane traffic and cell signalling. EMBO Rep. 2007;8(3):241-246.
9. Heck JN, Mellman DL, Ling K, et al. A conspicuous connection: Structure defines function for the phosphatidylinositol-phosphate kinase family. Crit Rev Biochem Mol Biol. 2007; 42(1):15-39.
10. Rameh LE, Tolias KF, Duckworth BC, Cantley LC. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature. 1997;390(6656):192-196.
11. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature. 1989;341(6239):197-205.
12. Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol. 2008;9(2):99-111.
13. Hay JC, Fisette PL, Jenkins GH, et al. ATPdependent inositide phosphorylation required for Ca(21)-activated secretion. Nature. 1995; 374(6518):173-177.
14. Clarke JH, Wang M, Irvine RF. Localization, regulation and function of type II phosphatidylinositol 5-phosphate 4-kinases. Adv Enzyme Regul. 2010; 50(1):12-18.
15. King CE, Hawkins PT, Stephens LR, Michell RH. Determination of the steady-state turnover rates of the metabolically active pools of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate in human erythrocytes. Biochem J. 1989;259(3):893-896.
16. Stephens LR, Hughes KT, Irvine RF. Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. Nature. 1991; 351(6321):33-39.
17. Roberts HF, Clarke JH, Letcher AJ, Irvine RF, Hinchliffe KA. Effects of lipid kinase expression and cellular stimuli on phosphatidylinositol 5-phosphate levels in mammalian cell lines. FEBS Lett. 2005;579(13):2868-2872.
18. Loijens JC, Anderson RA. Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family. J Biol Chem. 1996;271(51):32937-32943.
19. Ishihara H, Shibasaki Y, Kizuki N, et al. Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem. 1996;271(39):23611-23614.
20. Ishihara H, Shibasaki Y, Kizuki N, et al. Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J Biol Chem. 1998;273(15): 8741-8748.
21. Wang Y, Litvinov RI, Chen X, et al. Loss of PIP5KIgamma, unlike other PIP5KI isoforms, impairs the integrity of the membrane cytoskeleton in murine megakaryocytes [published correction appears in J Clin Invest. 2009;119(2):421]. J Clin Invest. 2008;118(2): 812-819.
22. Wang Y, Chen X, Lian L, et al. Loss of PIP5KIbeta demonstrates that PIP5KI isoform-specific PIP2 synthesis is required for IP3 formation [published correction appears in Proc Natl Acad Sci U S A. 2009;106(4):1291]. Proc Natl Acad Sci USA. 2008;105(37):14064-14069.
23. Wang Y, Zhao L, Suzuki A, et al. Platelets lacking PIP5KIg have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion. Blood. 2013;121(14):2743-2752.
24. Ling K, Doughman RL, Firestone AJ, Bunce MW, Anderson RA. Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. Nature. 2002;420(6911):89-93.
25. Di Paolo G, Pellegrini L, Letinic K, et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin. Nature. 2002;420(6911):85-89.
26. Gilmore AP, Burridge K. Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate. Nature. 1996;381(6582): 531-535.
27. Doughman RL, Firestone AJ, Wojtasiak ML, Bunce MW, Anderson RA. Membrane ruffling requires coordination between type Ialpha phosphatidylinositol phosphate kinase and Rac signaling. J Biol Chem. 2003;278(25): 23036-23045.
28. Padrón D, Wang YJ, Yamamoto M, Yin H, Roth MG. Phosphatidylinositol phosphate 5-kinase Ibeta recruits AP-2 to the plasma membrane and regulates rates of constitutive endocytosis. J Cell Biol. 2003;162(4):693-701.
29. Wenk MR, Pellegrini L, Klenchin VA, et al. PIP kinase Igamma is the major PI(4,5)P(2) synthesizing enzyme at the synapse. Neuron. 2001;32(1):79-88.
30. Calderwood DA, Ginsberg MH. Talin forges the links between integrins and actin. Nat Cell Biol. 2003;5(8):694-697.
31. Hartwig JH, Bokoch GM, Carpenter CL, et al. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell. 1995;82(4):643-653.
32. Gratacap MP, Payrastre B, Nieswandt B, Offermanns S. Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides. J Biol Chem. 2001;276(51): 47906-47913.
33. Yang SA, Carpenter CL, Abrams CS. Rho and Rho-kinase mediate thrombin-induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets. J Biol Chem. 2004;279(40): 42331-42336.
34. Chatah NE, Abrams CS. G-protein-coupled receptor activation induces the membrane translocation and activation of phosphatidylinositol-4-phosphate 5-kinase I alpha by a Rac- and Rhodependent pathway. J Biol Chem. 2001;276(36): 34059-34065.
35. Eyster KM. The membrane and lipids as integral participants in signal transduction: Lipid signal transduction for the non-lipid biochemist. Adv Physiol Educ. 2007;31(1):5-16.
36. Rhee SG, Choi KD. Multiple forms of phospholipase C isozymes and their activation mechanisms. Adv Second Messenger Phosphoprotein Res. 1992;26:35-61.
37. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem. 1997;272(24): 15045-15048.
38. Banno Y, Suzuki T, Nozawa Y. Isolation of a polyphosphoinositide-phospholipase C (Type b) from cytosolic and membrane fractions of human platelets. Platelets. 1992;3(2):69-77.
39. Banno Y, Yu A, Nakashima T, Homma Y, Takenawa T, Nozawa Y. Purification and characterization of a cytosolic phosphoinositidephospholipase C (gamma 2-type) from human platelets. Biochem Biophys Res Commun. 1990; 167(2):396-401.
40. Torti M, Lapetina EG. Role of rap1B and p21ras GTPase-activating protein in the regulation of phospholipase C-gamma 1 in human platelets. Proc Natl Acad Sci USA. 1992;89(16):7796-7800.
41. Blake RA, Schieven GL, Watson SP. Collagen stimulates tyrosine phosphorylation of phospholipase C-gamma 2 but not phospholipase C-gamma 1 in human platelets. FEBS Lett. 1994; 353(2):212-216.
42. Suzuki-Inoue K, Inoue O, Frampton J, Watson SP. Murine GPVI stimulates weak integrin activation in PLCgamma2-/- platelets: Involvement of PLCgamma1 and PI3-kinase. Blood. 2003;102(4):1367-1373.
43. Watson SP, Asazuma N, Atkinson B, et al. The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen. Thromb Haemost. 2001;86(1):276-288.
44. Suzuki-Inoue K, Inoue O, Ozaki Y. The novel platelet activation receptor CLEC-2. Platelets. 2011;22(5):380-384.
45. Ichise H, Ichise T, Ohtani O, Yoshida N. Phospholipase Cgamma2 is necessary for separation of blood and lymphatic vasculature in mice. Development. 2009;136(2):191-195.
46. Suzuki-Inoue K, Fuller GL, García A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542-549.
47. Brass LF, Joseph SK. A role for inositol triphosphate in intracellular Ca21 mobilization and granule secretion in platelets. J Biol Chem. 1985;260(28):15172-15179.
48. Lapetina EG, Reep B, Ganong BR, Bell RM. Exogenous sn-1,2-diacylglycerols containing saturated fatty acids function as bioregulators of protein kinase C in human platelets. J Biol Chem. 1985;260(3):1358-1361.
49. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007;7(4):281-294.
50. Lian L, Wang Y, Flick M, et al. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood. 2009;113(15):3577-3584.
51. Lee SB, Rao AK, Lee KH, Yang X, Bae YS, Rhee SG. Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood. 1996;88(5):1684-1691.
52. Yang X, Sun L, Ghosh S, Rao AK. Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: Evidence for defective phospholipase C activation. Blood. 1996;88(5): 1676-1683.
53. Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood. 2005;106(1):110-117.
54. Ji QS, Winnier GE, Niswender KD, et al. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad Sci USA. 1997;94(7): 2999-3003.
55. Wang D, Feng J, Wen R, et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity. 2000;13(1): 25-35.
56. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657.
57. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253(1):239-254.
58. Anderson KE, Jackson SP. Class I phosphoinositide 3-kinases. Int J Biochem Cell Biol. 2003;35(7):1028-1033.
59. Gibbins JM, Briddon S, Shutes A, et al. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem. 1998;273(51):34437-34443.
60. Hazeki O, Okada T, Kurosu H, Takasuga S, Suzuki T, Katada T. Activation of PI 3-kinase by G protein betagamma subunits. Life Sci. 1998; 62(17-18):1555-1559.
61. Tang X, Downes CP. Purification and characterization of Gbetagamma-responsive phosphoinositide 3-kinases from pig platelet cytosol. J Biol Chem. 1997;272(22):14193-14199.
62. Kubo H, Hazeki K, Takasuga S, Hazeki O. Specific role for p85/p110beta in GTP-bindingprotein-mediated activation of Akt. Biochem J. 2005;392(pt 3):607-614.
63. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G proteincoupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA. 2008; 105(24):8292-8297.
64. Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans. 2004; 32(pt 2):387-392.
65. Gratacap MP, Guillermet-Guibert J, Martin V, et al. Regulation and roles of PI3Kb, a major actor in platelet signaling and functions. Adv Enzyme Regul. 2011;51(1):106-116.
66. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA. 1997;94(9): 4330-4335.
67. Zhang J, Vanhaesebroeck B, Rittenhouse SE. Human platelets contain p110delta phosphoinositide 3-kinase. Biochem Biophys Res Commun. 2002;296(1):178-181.
68. Watanabe N, Nakajima H, Suzuki H, et al. Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. Blood. 2003;102(2):541-548.
69. Falet H, Barkalow KL, Pivniouk VI, Barnes MJ, Geha RS, Hartwig JH. Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR gamma-chain complex. Blood. 2000;96(12):3786-3792.
70. Heraud JM, Racaud-Sultan C, Gironcel D, et al. Lipid products of phosphoinositide 3-kinase and phosphatidylinositol 49,59-bisphosphate are both required for ADP-dependent platelet spreading. J Biol Chem. 1998;273(28):17817-17823.
71. Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94(12): 4156-4165.
72. Kauffenstein G, Bergmeier W, Eckly A, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001;505(2):281-290.
73. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood. 2004;104(6):1703-1710.
74. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004; 113(3):441-450.
75. Gilio K, Munnix IC, Mangin P, et al. Nonredundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. J Biol Chem. 2009;284(49): 33750-33762.
76. Canobbio I, Stefanini L, Cipolla L, et al. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood. 2009;114(10): 2193-2196.
77. Yap CL, Anderson KE, Hughan SC, Dopheide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood. 2002;99(1): 151-158.
78. Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood. 2004; 103(9):3403-3411.
79. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol. 2005;5(4):357-365.
80. Camps M, Rückle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11(9):936-943.
81. Rückle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: Towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 2006;5(11):903-918
82. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330.
83. Ali K, Bilancio A, Thomas M, et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature. 2004;431(7011): 1007-1011.
84. Senis YA, Atkinson BT, Pearce AC, et al. Role of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. Platelets. 2005; 16(3-4):191-202.
85. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194-204.
86. Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: Potential antithrombotic targets?. Cell Mol Life Sci. 2006; 63(10):1085-1090.
87. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J. 2001;15(11):2019-2021.